New Dual-Action antibody shows promise in early cancer trial
NCT ID NCT04606472
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have stopped responding to standard treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells by targeting two proteins (PD-1 and CTLA-4). The main goals are to find a safe dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Hubei Cancer Hospital
Wuhan, Hubei, China
-
Shanghai Central Hospital
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
-
Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.